医学
乳腺癌
肿瘤科
新辅助治疗
个性化医疗
内科学
基因组学
Pet成像
队列
前瞻性队列研究
乳房成像
队列研究
靶向治疗
癌症
生物标志物
精密医学
乳房磁振造影
梅德林
生物信息学
回顾性队列研究
无线电技术
分子成像
作者
Benlong Yang,Ming Chen,Panli Li,Xiao Xiao,Bingqiu Xiu,Jing Bai,Yuyun Sun,Xiaoping Xu,Jianping Zhang,Ying Qiao,Jingyan Xue,Zhimin Shao,Shaoli Song,Jiong Wu
标识
DOI:10.1097/js9.0000000000003931
摘要
BACKGROUND: We aimed to investigate potential biomarkers for predicting pathological complete response (pCR) to neoadjuvant therapy in HER2-positive breast cancer, with a focus on early-stage indicators. METHODS: We conducted a comprehensive analysis incorporating genomic and PET imaging data from 61 patients undergoing neoadjuvant treatment. Genomic profiling and PET/CT scans were performed at baseline (T1) and after one treatment cycle (T2). Various clinical and molecular parameters were assessed, including HER2 gene status, maximum standardized uptake value, and genomic alterations. RESULTS: Our findings revealed several candidate biomarkers associated with treatment response. Early changes in 18 F-FDG PET/CT and baseline 68 Ga-HER2 PET/CT emerged as potential predictors for pCR. Genomic analysis identified differences in mutation frequencies, with notable changes after one treatment cycle. A multivariate predictive model, incorporating PET imaging and clinical characteristics, demonstrated excellent performance in forecasting treatment response. CONCLUSIONS: The study underscores the significance of early biomarkers in predicting neoadjuvant treatment outcomes for HER2-positive breast cancer. Integrating genomic and imaging data provides a comprehensive approach for tailoring therapeutic strategies. The identified biomarkers hold promise for guiding treatment escalation or de-escalation, presenting a step forward in personalized management for HER2-positive breast cancer patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI